Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

不适用 进行中（已停止招募） NCT01385176

摘要

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Change in Left Ventricular End-systolic Dimension (LVESD)

LVESD at Baseline and at 6-months post Baseline · cm

Percentage of Surviving Participants

18-months · Percentage of participants surving

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

全部试验